Inclusion Criteria:  Written informed consent to participate in the study Man or woman 50-75 years of age Impaired glucose tolerance (IGT; capillary b-glucose 8.9-12.1 mmol/L, 120 minutes after OGTT), impaired fasting glucose (IFG; capillary b-glucose 6.1-6.9 mmol/L) or combined glucose intolerance (CGI, i.e. IFG and IGT) Weight stable ±5 kg for the last 3 months, BMI >18 kg/m2 Willingness and possibility to come to the planned study visits, use the Diary and eQuestionnaires as well as follow the study instructions Understand Swedish in speech and writing  Exclusion Criteria:  Other reasons for liver inflammation e.g. hepatitis A, hepatitis B, hepatitis C, HIV-positive, confirmed or suspected cirrhosis, Wilsons disease, autoimmune hepatitis, hemochromatosis, alcohol related fatty liver or pancreatitis, laboratory screen AST/ALT >2 (ULN), Bilirubin >1 (ULN) Heart failure NYHA class III, cardiovascular event within 6 months, unstable angina pectoris Diabetes mellitus, HbA1c >47 mmol/mol or fp-Glucose >6.9 mmol/L on 2 occasions Chronic obstructive pulmonary disease and asthma treated with intermittent steroids to be under control Blood pressure >170/105 mmHg Blood donation >500 mL blood <3 months before screening Anemia, Hb <117 g/L females and Hb <134 g/L males; leukopenia, LPK <3.5x1E9/L, ongoing infection CRP >10 mg/L Hyperthyroidism, T4 >22 nmol/L or hypothyroidism, TSH >4,2 mIU/L Laboratory result of clinical significance meaning that participation in the study is unsuitable according to Investigator Calculated glomerular filtration rate (GFR) <60 mL/min/1.73 m2 Cancer <5 years since diagnosis, except for basal-cell carcinoma Treatment during the last 3 months with oral steroids, biological drugs, immunosuppressive drugs, e.g. cyklosporin, drugs known to cause liver damage or to be liver toxic Bariatric surgery Antibiotic treatment during the last 3 months or reoccurring antibiotic treatment >3 times a year Regular or sporadic use of probiotic product (not food containing probiotics) during the last 3 months Confirmed IBD, irritable bowel syndrome (IBS), bile acid malabsorption, gastrointestinal infections during the last 3 months or any experienced problems from the gastrointestinal tract during the last month that the Investigator expect could influence the participation in the study Allergy to metronidazol, the adhesive glue for the CGM sensor, milk protein Smoking >10 cigarettes/day Alcohol consumption, >7 units/week females, >14 units/week males Use of narcotics e.g. cannabis, amphetamine (not medical use), hallucinogens, gamma-hydroxybutyric acid Pregnancy, breast-feeding or planned pregnancy Participation in other studies except IGT2